Entering text into the input field will update the search result below

Celsion: Still Waiting For Godot

Mar. 01, 2021 3:41 PM ETImunon, Inc. (IMNN)18 Comments


  • Today, we revisit biotech concern Celsion Corporation for the first time in over a half-decade.
  • The stock still trades right near the $2 level just like it did when we last took a look at this small-cap name in 2015.
  • News flow in 2021 has picked up, so it's time to circle back on Celsion. A full analysis is provided in the paragraphs below.
  • I do much more than just articles at The Biotech Forum: Members get access to model portfolios, regular updates, a chat room, and more. Get started today »

Today, we revisit a $2 biotech stock we last took a full look at in 2015. Despite the company's small size and lack of providing shareholder value over the years, the equity comes up occasionally over at The Biotech Forum as a Live Chat topic. Given how much time has elapsed since we last took more than a cursory glance at Celsion, we circle back on this small-cap name in the paragraphs below.

Company Overview:

Celsion Corporation (CLSN) is still a 'Tier 4' biotech concern based just outside of Philadelphia. The company remains focused on development of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. The shares trade right at two bucks a share and sport an approximate $130 million market cap.

ThermoDox® is Celsion’s lead product candidate. This compound is a proprietary heat-activated liposomal encapsulation of doxorubicin. ThermaDox is currently being evaluated in a global phase 3 clinical trial called OPTIMA evaluating it the treatment of primary liver cancer. Here is how the company describes ThermoDox is more granularity on its website.

ThermoDox leverages 2 facets of tumor biology:(1) tumors have leaky vasculature, which is permeable to liposomes and enables their accumulation within tumors, and (2) when heated, blood vessels in tumors become even more permeable, further increasing the accumulation of liposomes in tumors before releasing the doxorubicin. In animal models, ThermoDox has been shown to deliver 25 times more doxorubicin into tumors than does intravenous (IV) infusion alone, and 5 times more doxorubicin than standard liposomal formulations of the drug."

Celsion also has an earlier stage compound in pipeline called GEN-1. This produce candidate incorporates a DNA plasmid encoding IL-12 into a unique nanoparticle delivery system. GEN-1 immunotherapy is currently being evaluated in a phase I/II study named OVATION 2, in combination with chemotherapy, for newly diagnosed ovarian

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE.

This article was written by

Bret Jensen profile picture

Finding tomorrow's big winners in the lucrative biotech sector, The Biotech Forum focuses on proprietary, breaking research on promising biotech and biopharma stocks with significant potential for outsized alpha.  Our service offers a model 12 to 20 stock portfolio as well as Live Chat, weekly research and trade idea as well as market commentary and frequent portfolio updates.  

• • •

Specializing in profiling high beta sectors, Bret Jensen founded and also manages The Biotech Forum, The Insiders Forum, and the Busted IPO Forum model portfolios. Finding “gems” in the biotech and small-cap stock sectors, these highly volatile spaces proven hugely successful have empowered Bret Jensen's own investing portfolio.

• • •

Learn more about Bret Jensen's Marketplace Offerings:

The Insiders Forum | The Biotech Forum | Busted IPO Forum

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (18)

Thanks for your article on Celsion. In fact, your article is helping lot to future investors / new investors. I show insider buying in CLSN so started looking this Company and found your article and it helped me lot. So, please keep on writing these kind of articles.
Bret Jensen profile picture
@vipstock Thanks for the kind words. Best.
Certainly worth a hail mary trade here, new respectable board member, off loaded Thermodox, active options on occasion (they are being given away actually) Jan 2.5s, mercy mercy. Been buying more of all 2.5's most weeks as a spec, should the meme'ers get ahold of it, heavens to Betsy.
I don’t know why are you mostly writing about scam stocks
Nearly every stock you writ about will become scam
Bret Jensen profile picture
@Addy1992 Yep, I am a pump and dumper....what part of the conclusion of article was too difficult to understand?

"There are no notable trial milestones that are apparent in 2021. And, given how much shareholder value Celsion has destroyed over the past two decades, I see no real reason to own the shares at this moment in time."
Thanks for your article to focus people on this stock.Traded it from .71 to over 2.70 on the basis of a saucer shaped bottom from Aug. 2020 to Feb 2021.Taking another position today as it is near the 50 day MA with the 50 ready to cross the 200.Very tight stop, though, with the good points you brought up.This is a sentiment driven stock like NAK in the gold sector.News drives the price.Anyway, CLSN has had some high volume spikes the last few months, hoping for another.
fffgp profile picture
02 Mar. 2021
Bret, agree totally with your thinking, but.... I managed to snag a few shares near a bottom (admitted years ago, now) and am up somewhat. Recently started selling calls so this position is starting to turn into a nice little (VERY LITTLE) gold mine. My Mar5C expires soon, so I am looking at the Jul5C. Pretty juicy premium. Rinse/repeat. Thanks again for turning me on to the CC/BW strategy.
Bret Jensen profile picture
@fffgp YW....whatever works....sometimes a stock that trades sideways for years (EX, AGEN) can be an investors best friend with that strategy.
@fffgp you didn't buy this years ago and are sitting on anything other than a huge loss. Stop lying.
I've held a small position for years and I rode it to the bottom. I think my break even is $55.00 a share now. I can't remember how many times they split it to keep up the value. It's a joke.
Not the same $2 stock as 2015. Down 98% since 2015.
xXgodFatherXx profile picture
Keep waiting while Biocryst is printing
@xXgodFatherXx I asked before in anotgr comments section-- Did Bret miss that one and you are unhapoy about it? You give no explanation for the snarkiness. L
Can you let us all in on your apparent anger as to why?
tammer profile picture
Wondering why the companies you follow are more suited to the "pink sheets."
Bret Jensen profile picture
@tammer Really? Did I recommend this stock? Were not my last two articles on SUPN and KDMN? Are these 'pink sheet' stocks?
@tammer that's a funny way to say "thanks for the free analysis and short suggestion."
aaronr89 profile picture
They announced failure of optima in July of last year.
@aaronr89 And again 3 weeks ago
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.